Antibe Therapeutics Releases Secondary Endpoint Data for Lead Drug

 Antibe Therapeutics released positive secondary endpoint data from the recent Phase 2B Gastrointestinal safety study for its lead drug, ATB-346. These results are consistent with the primary endpoint data, previously released in March 2018. 

Click here to see the press release. 

Previous
Previous

Investor Spotlights: Amgen and AmorChem - JLABS Toronto

Next
Next

Reviewing 'Formulating a Non-Dilutive Fundraising Strategy', Part 2 of OBIO's 'Building Your Early-Stage Strategy Toolbox' Event